ACAD
ACADIA PHARMACEUTICALS INC.Marquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q2 2022 | 17Q | $17 | $21 | +23% |
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $16 | $21 | +32% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $15 | $21 | +37% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $15 | $21 | +37% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $15 | $21 | +37% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $15 | $21 | +37% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $15 | $21 | +37% |
| Point72 Asset Management re-entered | Q3 2024(8Q snapshot) | 7Q | $15 | $21 | +37% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Duquesne Family Office | Q3 2021 | Q4 2023 | → $23 | +38% |
| Maverick Capital | Q1 2021 | Q2 2021 | → $21 | -57% |
| Elliott Management | Q2 2017 | Q1 2018 | → $31 | +7% |
| JANA Partners | Q4 2016 | Q3 2017 | → $32 | +10% |
| Viking Global Investors | Q1 2014 | Q2 2015 | → $39 | +64% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at ACADIA PHARMACEUTICALS INC. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 2, 2026 — the most recent Form 4 on file — not from today.
- Form 40001193125-26-253632Jun 2, 2026
- Form 40001177917-26-000009Jun 1, 2026
- Form 40001865210-26-000002Jun 1, 2026
- Form 40001365619-26-000002Jun 1, 2026
- Form 40001604689-26-000009Jun 1, 2026
- Form 40001826361-26-000002Jun 1, 2026
- Form 40001560782-26-000002Jun 1, 2026
- Form 40001816160-26-000008May 27, 2026
- Form 40001816160-26-000007May 5, 2026
- Form 40001899977-26-000007May 5, 2026
- Form 40001899977-26-000005Apr 7, 2026
- Form 40001816160-26-000005Apr 7, 2026
- Form 40001816838-26-000003Mar 26, 2026
- Form 40001861477-26-000003Mar 26, 2026
- Form 40001568249-26-000005Mar 26, 2026
Fundamentals
XBRL · ACADIA PHARMACEUTICALS INC.Annual figures sourced directly from ACADIA PHARMACEUTICALS INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for ACADIA PHARMACEUTICALS INC — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 29, 2026
- 10-QQuarterly reportMay 7, 2026
- 8-KMaterial eventMay 6, 2026
- 8-KMaterial eventMay 1, 2026
- DEF 14AProxy statementApr 24, 2026
- 8-KMaterial eventMar 5, 2026
- 10-KAnnual reportFeb 26, 2026
- 8-KMaterial eventFeb 25, 2026
- 8-KMaterial eventJan 13, 2026
- 10-QQuarterly reportNov 6, 2025
- 8-KMaterial eventNov 5, 2025
- 8-KMaterial eventNov 3, 2025
- 10-QQuarterly reportAug 7, 2025
- 8-KMaterial eventAug 6, 2025
- 8-KMaterial eventJun 10, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Bridgewater Associates | Q4 2025 | open | $24 | $21 | -12% |
| Point72 Asset Management | Q1 2025 | open | $20 | $21 | +3% |
| Citadel Advisors | Q3 2024 | open | $15 | $21 | +37% |
| Two Sigma Investments | Q3 2024 | open | $15 | $21 | +37% |
| D.E. Shaw | Q3 2024 | open | $15 | $21 | +37% |
| AQR Capital Management | Q3 2024 | open | $15 | $21 | +37% |
| Millennium Management | Q3 2024 | open | $15 | $21 | +37% |
| Point72 Asset Management | Q3 2024 | Q4 2024 | $15 | $17 | +12% |
| Renaissance Technologies | Q3 2024 | open | $16 | $21 | +32% |
| Bridgewater Associates | Q2 2022 | Q4 2022 | $17 | $16 | -3% |
| Duquesne Family Office | Q3 2021 | Q4 2023 | $17 | $23 | +38% |
| Maverick Capital | Q1 2021 | Q2 2021 | $49 | $21 | -57% |
| Elliott Management | Q2 2017 | Q1 2018 | $29 | $31 | +7% |
| JANA Partners | Q4 2016 | Q3 2017 | $29 | $32 | +10% |
| Viking Global Investors | Q1 2014 | Q2 2015 | $24 | $39 | +64% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.